- Conditions
- Obesity, Overweight, or Chronic Weight Management
- Interventions
- aleniglipron or placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Chicago, Illinois • Richfield, Minnesota + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Clear all
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Interventions
- aleniglipron or placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Glendale, California • Montclair, California • Valparaiso, Indiana + 7 more
- Conditions
- Healthy Volunteers
- Interventions
- GSBR-1290, Placebo
- Drug · Other
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Healthy Volunteers
- Interventions
- GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet)
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Miami, Florida • Baltimore, Maryland
- Conditions
- Obesity, Overweight, or Chronic Weight Management
- Interventions
- Aleniglipron or Placebo, Aleniglipron
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Interventions
- aleniglipron, Placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 68 more
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Interventions
- Aleniglipron, Placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 3,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 64 more
- Conditions
- Overweight or Obesity, Type2 Diabetes Mellitus
- Interventions
- GSBR-1290, Placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Anaheim, California • Chula Vista, California • Miami, Florida + 1 more
- Conditions
- Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
- Interventions
- Aleniglipron, Placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 16
- States / cities
- Anniston, Alabama • Lake Forest, California • Lomita, California + 11 more